Income Statement (TTM)
Terns Pharmaceuticals, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
|
|---|---|---|---|---|
| Revenue | 1 | 1 | 1 | 1 |
| Change (%) | 0.00 | 0.00 | 0.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | ||||
| Change (%) | ||||
| % of Revenue | ||||
| Gross Operating Profit | 1 | 1 | 1 | 1 |
| Change (%) | 0.00 | 0.00 | 0.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 |
| SG&A | 20 | 21 | 21 | 22 |
| Change (%) | 5.77 | 2.73 | 1.96 | |
| % of Revenue | 1,954.90 | 2,067.70 | 2,124.20 | 2,165.80 |
| R&D | 31 | 31 | 33 | 38 |
| Change (%) | -1.91 | 8.79 | 14.99 | |
| % of Revenue | 3,131.10 | 3,071.20 | 3,341.30 | 3,842.10 |
| OpEx | 51 | 51 | 55 | 60 |
| Change (%) | 1.04 | 6.36 | 9.92 | |
| % of Revenue | 5,086.00 | 5,138.90 | 5,465.50 | 6,007.90 |
| Operating Income | -50 | -50 | -54 | -59 |
| Change (%) | 1.06 | 6.48 | 10.11 | |
| % of Revenue | -4,986.00 | -5,038.90 | -5,365.50 | -5,907.90 |
| Interest Expense | ||||
| Change (%) | ||||
| % of Revenue | ||||
| Net Income | -50 | -51 | -54 | -59 |
| Change (%) | 0.87 | 6.31 | 9.27 | |
| % of Revenue | -5,015.80 | -5,059.40 | -5,378.60 | -5,877.10 |
Source: Capital IQ
